normal saline + dexmedetomidine + propofol + sufentanil

**normal saline + dexmedetomidine + propofol + sufentanil** is a multi-component drug regimen used for procedural sedation, specifically evaluated in clinical trials for patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP). This combination, studied under the sponsorship of Shiyou Wei, utilizes the synergistic effects of three primary active agents: dexmedetomidine (a selective alpha-2 adrenergic agonist), propofol (a sedative-hypnotic acting on GABA-A receptors), and sufentanil (a potent mu-opioid analgesic). In the specific protocol identified, normal saline is administered via nasal spray as a placebo control, while dexmedetomidine, propofol, and sufentanil are administered intravenously to achieve and maintain deep sedation (BIS 40-60). The regimen aims to provide balanced hypnosis and analgesia while minimizing common side effects such as respiratory depression and intraoperative hypoxemia.

Other names

normal saline + dexmedetomidine + propofol + sufentanil-Shiyou Wei-procedural sedationNormal Saline (nasal spray) + Dexmedetomidine Injection (intravenous) + Propofol Injection + Sufentanil Injection